Two days later, the same participant's routine laboratory panel returns with alanine aminotransferase at 11 times the upper limit of normal. The investigator reviews the result, confirms it is clinically significant, and the coordinator documents the event as hepatotoxicity. The coordinator reaches for the Investigator's Brochure again. The IB's safety section lists "transaminase elevation" as a known finding. But the participant's clinical picture -- markedly elevated transaminases with early signs of synthetic dysfunction -- may represent a severity and specificity that goes beyond the mild, transient elevations described in the IB. Is this expected?

That question -- seemingly simple, fundamentally consequential -- determines whether this event is classified as a Suspected Unexpected Serious Adverse Reaction. And that classification triggers a cascade: expedited reporting to regulatory authorities, notification to all investigators worldwide, potential protocol amendments, possible trial suspension. The difference between "expected" and "unexpected" is not a matter of semantics. It is the fulcrum on which the most urgent safety reporting obligations pivot.

This lesson teaches you what expectedness means, where to find the reference document that defines it, and -- critically -- whose job it is to make the determination. The CRC does not decide expectedness. But the CRC's documentation is what makes accurate expectedness assessment possible.

Two days later, the same participant's routine laboratory panel returns with alanine aminotransferase at 11 times the upper limit of normal. The investigator reviews the result, confirms it is clinically significant, and the coordinator documents the event as hepatotoxicity. The coordinator reaches for the Investigator's Brochure again. The IB's safety section lists "transaminase elevation" as a known finding. But the participant's clinical picture -- markedly elevated transaminases with early signs of synthetic dysfunction -- may represent a severity and specificity that goes beyond the mild, transient elevations described in the IB. Is this expected?

That question -- seemingly simple, fundamentally consequential -- determines whether this event is classified as a Suspected Unexpected Serious Adverse Reaction. And that classification triggers a cascade: expedited reporting to regulatory authorities, notification to all investigators worldwide, potential protocol amendments, possible trial suspension. The difference between "expected" and "unexpected" is not a matter of semantics. It is the fulcrum on which the most urgent safety reporting obligations pivot.

This lesson teaches you what expectedness means, where to find the reference document that defines it, and -- critically -- whose job it is to make the determination. The CRC does not decide expectedness. But the CRC's documentation is what makes accurate expectedness assessment possible.